Trial Profile
A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Celltrion
- 29 Nov 2023 This trial has been completed in Hungary (Date of the global end of the trial: 19-Sep-2023), according to the European Clinical Trials Database record.
- 27 Oct 2023 This trial has been completed in Poland (global end date: 2023-09-19), according to European Clinical Trials Database.
- 01 Jan 2023 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.